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Abstract
Background: The application of adaptive design methodology within a clinical trial setting is becoming
increasingly popular. However the application of these methods within trials is not being reported as adaptive
designs hence making it more difficult to capture the emerging use of these designs. Within this review, we aim to
understand how adaptive design methodology is being reported, whether these methods are explicitly stated as an
‘adaptive design’ or if it has to be inferred and to identify whether these methods are applied prospectively or
concurrently.
Methods: Three databases; Embase, Ovid and PubMed were chosen to conduct the literature search. The inclusion
criteria for the review were phase II, phase III and phase II/III randomised controlled trials within the field of
Oncology that published trial results in 2015. A variety of search terms related to adaptive designs were used.
Results: A total of 734 results were identified, after screening 54 were eligible. Adaptive designs were more
commonly applied in phase III confirmatory trials. The majority of the papers performed an interim analysis, which
included some sort of stopping criteria. Additionally only two papers explicitly stated the term ‘adaptive design’ and
therefore for most of the papers, it had to be inferred that adaptive methods was applied. Sixty-five applications of
adaptive design methods were applied, from which the most common method was an adaptation using group
sequential methods.
Conclusions: This review indicated that the reporting of adaptive design methodology within clinical trials needs
improving. The proposed extension to the current CONSORT 2010 guidelines could help capture adaptive design
methods. Furthermore provide an essential aid to those involved with clinical trials.
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Background
In recent years, there has been a rise of interest in adap-
tive design methodology [1, 2]. The Food and Drug Ad-
ministration (FDA) define an adaptive design as “a study
that includes a prospectively planned opportunity for
modification of one or more specified aspects of the
study design and hypotheses based on analysis of data
from subjects in the study” [3]. Conversely Chow and
Chang (2008) have broadened this definition by classifying
adaptive designs as any modifications made prospectively,
concurrently or retrospectively during the conduct of a
trial.
The implementation of adaptive designs can have po-
tential benefits in clinical trials over other study designs
such as parallel design, crossover etc. [4]. They can be
more efficient, more cost effective, the likelihood of suc-
cess increases, and there is an improved understanding
of treatment success [1, 4, 5], however these benefits are
only possible if the validity and integrity of the proposed
study isn’t undermined [1]. Furthermore adaptive design
methods may appeal more to clinical investigators due
to the flexibility and prospect of making changes based
on data at an interim stage of the trial.
Previous reviews into the application of adaptive design
methodology have already been conducted. For example,
Bauer (2006) conducted a review to investigate papers that
were published between the years 1989 and 2004. The pur-
pose of their review was to explore the impact of adaptive
design methodology in medicine, particularly those designs
based on the combination test or conditional error func-
tion, and to see if these methods were applied and pre-
sented appropriately [6]. A review conducted by Stevely
(2015) assessed the standards of phase III group sequential
randomised controlled trials (RCT) against the CONSORT
2010 checklist [7]. This review looked at papers published
between 1st January 2001 and 23rd September 2014. Eli-
gible papers were found in 11 different therapeutic fields, of
which the majority (76%) were found in the field of oncol-
ogy. This review concluded that there were issues with the
reporting of group sequential trials and hence suggest an
extension to the CONSORT checklist to help solve this
problem. A recently published review by Hatfield (2016) ex-
amines the state of phase II, II/III and III adaptive design
trials registered between the years 2000 and 2014. The
ClinicalTrials.gov website and National Institute for Health
Research register were used to collate registered trials with
adaptive designs. Of all the registered trials with adaptive
designs, the review found that adaptive designs are most
often used in the field of oncology. The review did not suc-
cessfully capture all trials with adaptive designs, and hence
suggested that clinical trial registers should dedicate sec-
tions for adaptive designs and encourage the use of the
term ‘adaptive design’ in either the title, summary or design
sections of the register [8].
The aforementioned reviews have looked into spe-
cific methods related to adaptive design methodology
or attempted to find all adaptive designs registered on
Clinical trial registries. It is unclear the current extent
of applications of adaptive design methodology specif-
ically in oncology trials and whether reporting has
improved over time. Therefore this literature review
specifically attempts to capture papers published in
2015 that are using adaptive design methodology
within phase II, II/III or III RCT in the field of On-
cology. This review aims to understand how adaptive
design methodology is currently being reported within
journals, whether these methods are being applied pro-
spectively or concurrently, what methods are commonly
applied and to understand whether the use of adaptive de-
sign methodology is being explicitly stated or whether it
has to be inferred. Furthermore this review will suggest ex-
tensions to the CONSORT that can be implemented to aid
better reporting and to maximise the capture of adaptive
design methodology.
Methods
Literature search
The Embase, Ovid and PubMed databases were
chosen to conduct the literature search into the appli-
cation of adaptive design methodology. The review
was constrained to phase II, phase III or phase II/III
RCT’s with patients diagnosed with cancer that pre-
sented primary outcome trial results and were pub-
lished in 2015. Eligible papers should indicate the use
of adaptive design methodology, papers should be full
text publications in the English language and access-
ible. Duplicate records were excluded based on the
title, authors, abstract and year of publication. All re-
quired data were extracted and recorded on an excel
spreadsheet.
The definition that will be used to identify the ap-
plication of adaptive design methodology will be any
potential modifications made to the trial/statistical
procedure that is either prospective, ad-hoc or retro-
spective [1, 9].
A free text search was conducted to capture phase II,
II/III, or IIII Cancer RCTs, the following keywords were
used: “phase II(2)”, “phase III(3)”, “phase II(2)/III(3)”,
“Oncology”, “Cancer”, “Neoplasm”, “Carcinoma”, “ran-
domis(z)ed controlled trial(s)”, “randomis(z)ed clinical
trial(s)”, “trial”, “controlled clinical trial(s)”. To capture
as many results related to adaptive design methodology
within these trials, the following keywords were used
alongside the Boolean operator “OR”: “adaptive design(s)”,
“flexible design(s)”, “group sequential”, “adaptive rando-
mis(z)ation”, “sample size re-estimation”, “sample size ad-
justment”, “sample size modification”, “MAMS”,
“multi(−)arm multi(−)stage”, “multi(ple) arm”, “multi(ple)
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stage”, “interim analysi(e)s”, “adaptive seamless”, “bio-
marker adaptive”, “adaptive clinical trial(s)”, “two-stage
adaptive”, “multiple adaptive”, “adaptive enrichment”,
“dose escalation”, “dose selection”, “drop the loser”, “pick
the winner” and “treatment switch(ing)”.
Data extraction
An excel spreadsheet was used to record the following
data:
– Standard demographics such as first author, title,
name of the trial;
– The journal that the paper was published in;
– The funder or sponsor of the study;
– The phase of the trial;
– The type of cancer being reported;
– The nature of the primary outcome;
– The number of trial arms;
– The type of intervention being implemented;
– The number of any planned interim analyses;
– The stage of the trial being reported, i.e. interim or
final analysis;
– Any planned stopping criteria and reason;
– Whether the trial was terminated early and the
reason for early stopping;
– The initial planned sample size and the reported
sample size;
– The adaptive designs methodology used;
– The number of adaptive designs that were applied;
– Whether the adaptive design was predetermined or
concurrent;
– Whether the use of adaptive designs was explicitly
stated;
– The trial identifier if it had been registered on
clinical trial websites.
The papers identified by the literature search were
all reviewed and information extracted and recorded
in the aforementioned excel spreadsheet. Data that
could not be found in the paper was researched by
using the trial identifier or trial name to find out the
relevant information. If no further information was
available then the data was classified as missing. One
person (PM) extracted the information from the pa-
pers and any papers that needed further clarification
were checked and validated by two reviewers as a
form of quality control (AM and JD).
Results
A total of 8288 records were identified related to
RCTs in the field of Oncology that were published in
2015 across the Ovid, Embase and PubMed databases.
Of which 734 records were identified using the key
search terms mentioned above that were related to
adaptive designs within the phase II, phase II/III and
phase III trial setting.. After the removal of duplicates
464 records were screened, of which 368 records were
excluded due to the following reasons: published ab-
stract only (n = 263), not related to the literature re-
view (n = 66), either methodology or review papers
hence would not contain results (n = 33) or the full
reports were inaccessible (n = 6). The remaining 96
full text records were further assessed for eligibility,
of which 42 were excluded for the following reasons:
not a RCT (n = 29), not cancer related (n = 3), not
the analysis of the primary outcome (n = 9) or no in-
formation provided (n = 1). This left a total of 54 re-
cords for analysis (Fig. 1) (see Additional file 1 for
the full list of titles for each paper).
Of the 54 papers reviewed, 38 papers (70%) were phase
III confirmatory trials, 12 out of 54 papers (22%) were
phase II trials, 2 (4%) were phase IIb trials and 2 (4%)
were phase II/III trials. The number of arms in a trial
ranged from two to five arms, 46 (85%) papers were two
arm trials of which 35 of these were phase III trials, 10
of the two arm trials were phase II trials, there was 1
four arm phase III trial and 1 five arm phase II/III trial
(Table 1).
The literature review identified adaptive trials being
reported in 21 different journals (Appendix 1). Of these
the Journal of Clinical Oncology published the highest
number of papers with 12 out of 54 papers (22%),
followed by the Lancet Oncology with 11 papers (21%),
then the New England Journal of Medicine with 6 papers
(11%) and the European Journal of Cancer publishing 3
papers (6%). The remaining 17 journals published either
one or two papers (Appendix 1).
There were 45 out of 54 (81%) papers that had a time
to event outcome as its primary outcome (Appendix 2).
Furthermore 49 out of 54 (92%) were drug related trials
(Appendix 3).
Of the 54 papers reviewed, 33 (61%) were published
based on results during an interim analysis, the re-
sults of the remaining papers were based on either
final analysis (20/54) or subgroup analysis (1/54). Of
the 33 papers published based on results during an
interim analysis, 26 papers resulted in the trial stop-
ping early, of which all 26 had a pre-planned stopping
criteria that stopped early due to either safety/effi-
cacy/futility i.e. group sequential methods (Table 2).
The remaining 7 papers stated to continue with the
trial as planned. The majority of the papers (48/54)
had a pre-planned interim analysis with 34 out of the
48 specifying one interim analysis during the course
of the trial, 9 specifying two interim analyses, 3 speci-
fying three interim analyses and the remaining 2 pa-
pers conducting interim analyses annually during the
course of the trial.
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Majority of trials applied a single adaptive design
method (44/54 papers, 80%), 9 out of 54 papers
(19%) applied two methods and 1 paper (2%) applied
three methods. In total there were 65 applications of
adaptive design methods, of which the most reported
method was adaptations using group sequential
methods with 50 out of 65 applications, followed by
dose modifications (8/65), sample size re-estimation
(4/65), adaptive randomisation (1/65),) change in pri-
mary endpoint (1/65) and change in patient eligibility
(1/65).
Table 3 shows the different variables extracted split by
the adaptive method applied. All papers that applied group
sequential methods had incorporated a planned stopping
criteria. Furthermore 35/50 of these group sequential
methods were in a phase III setting. All 4 papers that im-
plemented sample size re-estimation methods resulted in
the trial stopping early. Additionally 3 out of 4 of these pa-
pers had both pre-determined and ad-hoc applications of
adaptive design methods. Conversely all papers that applied
dose modification methods had pre-determined the use of
adaptive design methods.
Of the 54 papers reviewed, 49 (91%) had predeter-
mined the use of adaptive design methods, 1 paper
had applied ad-hoc adaptive design methods and 4
papers had predetermined and ad-hoc use of adaptive
design methods. However only 2 out of 54 papers
(4%) had explicitly used the phrase ‘adaptive design’
Table 1 Two way table of phase of a trial and number of trial
arms it has
Trial phase Number of arms Total
2 3 4 5
Phase II 10 2 0 0 12
Phase IIb 1 1 0 0 2
Phase II/III 0 1 0 1 2
Phase III 35 2 1 0 38
Total 46 6 1 1 54
Table 2 Two way table of whether the trial stopped early
compared to if the trial had a planned stopping criteria
Trial stopped
early
Pre-planned stopping criteria Total
No Yes Unknown
No 5 22 1 28
Yes 0 26 0 26
Total 5 48 1 54
Fig. 1 Modified PRIMSA flow diagram showing the review process
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to explain that adaptive methodology was applied, the
remaining papers indicated the use of adaptive design
methods. Of the papers that explicitly stated the use
of adaptive design methodology, one paper had imple-
mented a Bayesian adaptive response design which in-
cluded adaptive randomisation and dose modification.
The other paper applied multiple adaptive methods
which included the use of group sequential methods,
sample size re-estimation, and dose modification.
Discussion
This literature review aimed to understand the report-
ing of adaptive design methodology in RCTs in par-
ticular within the field of oncology. This review has
highlighted that the reporting of these methods needs
improving, which confirms the outcome of other re-
views. Stevely et al. reported that there are issues
related to the reporting of group sequential trials and
suggested a consort extension to alleviate the issues
related to this [7]. Hatfield et al. emphasises the need
for improving the way adaptive designs are reported
and suggests a modification to the CONSORT state-
ment [8]. Additionally Bauer and Einfalt suggest that
the presentation of adaptive design methodology
needs to be developed [6].
The classifications of the adaptive design methods
were based upon those mentioned by the FDA. One
form of adaptive design methods are those using
group sequential methods, these methods have been
used extensively for a number of years hence the ro-
bustness of these methods have qualified them to be
known as well understood methods by the regulators
[3, 10]. This design employs stopping boundaries at
regular interims to assist in decision making with
Table 3 The data extracted split by the adaptive method applied
Data extracted Adaptive method applied
Group sequential
methods (n = 50)
Dose modifications
(n = 8)
Sample size re-
estimation (n = 4)
Adaptive
randomisation (n = 1)
Change in primary
endpoint (n = 1)
Change in patient
eligibility (n = 1)
Trial phase
II 13 2 0 1 0 0
II/III 2 1 1 0 0 0
III 35 5 3 0 1 1
Number of arms
2 42 7 2 1 1 1
3 6 1 0 0 0 0
4 1 0 1 0 0 0
5 1 0 1 0 0 0
Stage of reporting
Interim analysis 33 2 2 0 1 1
Subgroup analysis 0 1 0 0 0 0
Final analysis 17 5 2 1 0 0
Planning of adaptive design method
Pre-determined 45 8 1 1 0 1
Ad-hoc 1 0 0 0 0 0
Both 4 0 3 0 1 0
Explicitly stated Adaptive design
Yes 1 1 1 1 0 0
No 49 7 3 0 1 1
Planned stopping criteria
Yes 50 5 4 0 1 1
No 0 3 0 1 0 0
Trial stopped early
Yes 26 1 4 0 1 0
No 24 7 0 1 0 1
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Table 4 Proposed extensions to the current CONSORT diagram [15]
Section/Topic Item No Standard Checklist item Extension for adaptive designs
Title and abstract
1a Identification as a randomised trial in the title Identification as an adaptive randomised
trial if it is an adaptive design
1b Structured summary of trial design, methods,
results, and conclusions (for specific guidance
see CONSORT for abstracts [16, 17])
Include the term ‘adaptive design’ or ‘
adaptive methods’
Introduction
Background and objectives 2a Scientific background and explanation of
rationale
Rational for implementing an adaptive design
2b Specific objectives or hypotheses
Methods
Trial design 3a Description of trial design (such as parallel,
factorial) including allocation ratio
Define what adaptive design/ adaptive method
will be applied
3b Important changes to methods after trial
commencement (such as eligibility criteria),
with reasons
Any changes during the trial should be reported
as an adaptive method.
Participants 4a Eligibility criteria for participants Any changes in eligibility during the trial, should
be classed as an adaptive design or adaptive
method.
4b Settings and locations where the data were
collected
Interventions 5 The interventions for each group with sufficient
details to allow replication, including how and
when they were actually administered
Outcomes 6a Completely defined pre-specified primary and
secondary outcome measures, including how and
when they were assessed
6b Any changes to trial outcomes after the trial
commenced, with reasons
Any changes during the trial are classed as an
adaptive method and should be mentioned.
Sample size 7a How sample size was determined Any changes to sample size or power during
trial classed as an adaptive design or adaptive
method and should be mentioned.
7b When applicable, explanation of any interim
analyses and stopping guidelines
Explain why the interim analysis will be taking
place, if potential pre-planned adaptations
during interim analysis taking place then these
should be mentioned in the methods as well
(3b). Include details of any planned stopping
boundaries for either the trial or dropping any
of the intervention arms.
Randomisation:
Sequence generation 8a Method used to generate the random allocation
sequence
8b Type of randomisation; details of any restriction
(such as blocking and block size)
Details if adaptive randomisation has been
implemented.
Allocation concealment
mechanism
9 Mechanism used to implement the random allocation
sequence (such as sequentially numbered containers),
describing any steps taken to conceal the sequence
until interventions were assigned
Implementation 10 Who generated the random allocation sequence,
who enrolled participants, and who assigned
participants to interventions
Blinding 11a If done, who was blinded after assignment to
interventions (for example, participants, care
providers, those assessing outcomes)
and how
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Table 4 Proposed extensions to the current CONSORT diagram [15] (Continued)
11b If relevant, description of the similarity
of interventions
Statistical methods 12a Statistical methods used to compare groups
for primary and secondary outcomes
Details of how the adaptive design or the
adaptive methods were applied Details of
how the statistical methods were evaluated
before implementation i.e. through the use
of simulations?
12b Methods for additional analyses, such
as subgroup analyses and adjusted analyses
Results
Participant flow (a diagram is
strongly recommended)
13a For each group, the numbers of participants
who were randomly assigned, received
intended treatment, and were analysed for
the primary
outcome
Ensure any adaptations are shown on this
diagram, such as dropping of arms, treatment
switching.
13b For each group, losses and exclusions after
randomisation, together with reasons
Recruitment 14a Dates defining the periods of recruitment
and follow-up
14b Why the trial ended or was stopped Any changes to recruitment during trial classed
as an adaptive method, should be mentioned.
Baseline data 15 A table showing baseline demographic
and clinical characteristics for each group
Numbers analysed 16 For each group, number of participants
(denominator) included in each analysis
and whether the analysis was
by original assigned groups
Outcomes and estimation 17a For each primary and secondary outcome,
results for each group, and the estimated
effect size and its precision (such
as 95% confidence interval)
17b For binary outcomes, presentation of both
absolute and relative effect sizes
is recommended
Ancillary analyses 18 Results of any other analyses performed,
including subgroup analyses and adjusted
analyses, distinguishing pre-specified
from exploratory
Harms 19 All important harms or unintended effects
in each group (for specific guidance see
CONSORT for harms [18])
Discussion
Limitations 20 Trial limitations, addressing sources of
potential bias, imprecision, and, if relevant,
multiplicity of analyses
Generalisability 21 Generalisability (external validity, applicability)
of the trial findings
If ad-hoc adaptive methods were implemented,
at what point was it decided to implement this
and why.
Interpretation 22 Interpretation consistent with results,
balancing benefits and harms, and
considering other relevant evidence
Registration 23 Registration number and name of
trial registry
Protocol 24 Where the full trial protocol can be
accessed, if available
First and last protocol, with a list of amendments
made.
Funding 25 Sources of funding and other support
(such as supply of drugs),
role of funders
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regards to the trial or treatment. Many methods such
as Simon’s two-stage design, O’Brien and Fleming
design, multi-arm multi-stage designs can be in-
cluded within the umbrella of group sequential de-
signs [11–14]. Hence any papers that employed the
aforementioned designs or applied methods whereby
trial/treatment related decisions could be made during
an interim analysis were classed as group sequential
methods. It was found from the literature review that
group sequential methods were used within 50 out of
65 applications.
The review found that majority of the papers (53/
54) applied adaptive methods that were prospectively
planned hence supporting the definition given by the
FDA. The list of search terms helped in capturing ap-
plications of adaptive design methodology however
only two papers explicitly stated the term ‘adaptive
design’ and it was inferred from the remaining papers
that adaptive design methodology was used.
The reporting of these studies has not improved and
hence this review supports the need for a set of guide-
lines of how adaptive designs should be reported. A pro-
posed extension to the current CONSORT 2010
guidelines has been made (Table 4). This extension
should be used for any trials that fit the definition of
adaptive designs as used for this literature review, i.e. for
trials with any modifications made to the trial/statistical
procedure that was either prospective, ad-hoc or retro-
spective. The justification for attempting to create an ex-
tension to the CONSORT guidelines is to ensure that as
many adaptive design based trials are captured. A crucial
question that needs to be answered is ‘at what point
exactly a trial become classed as adaptive?’ Table 4 can
assist that decision for those involved in the running of
a trial.
Pragmatically this extended CONSORT would greatly
assist in efficient capturing of published papers related
to adaptive design methodology. Furthermore extending
the CONSORT 2010 guidelines would encourage greater
capture of predetermined adaptations which would
greatly benefit all those involved in clinical trials ensur-
ing explicit and thorough reporting of the adaptive na-
ture of RCTs and the methodology used. It will allow
full transparency of all adaptations carried out during
the trial.
Conclusions
It can be concluded that the reporting of adaptive
design methodology within RCT’s is inadequate and
requires improvement. To assist in the capture of
adaptive design methods the proposed extension to
the CONSORT 2010 guidelines can be implemented;
this will also prove to be a crucial aid to all members
involved with clinical trials.
Appendix 1
T5
Appendix 2
T6
Appendix 3
T7
Table 5 List of journals from which the papers were published in
Journal Frequency
Annals of Oncology 2
BMC Research Notes 1
Breast Cancer Research & Treatment 1
British Journal of Haematology 2
Cancer 2
Cancer Management and Research 1
Clinical Cancer Research 1
Clinical Lung Cancer 2
Drug design, development & therapy 1
European Urology 1
European Journal of Cancer 3
Gynaecologic Oncology 2
Head & Neck 1
Journal of American Medical Association 1
Journal of Clinical Oncology 12
Journal of Urology 1
Lancet Oncology 11
Molecular Cancer Therapeutics 1
New England Journal of Medicine 6
Leukemia 1
Radiotherapy & Oncology 1
Total 54
Table 6 List of primary outcomes of the papers
Primary outcome Frequency
Bowel movement/Flushing episodes 1
Cytogenic Response 2
Disease Control Rate 1
Optimal dose 1
Overall pain response 1
Response to treatment 1
Success/Failure 2
Time to event outcome 45
Total 54
Table 7 List of categorised interventions of the papers
Intervention Frequency
Adding acid 1
Drug 49
Surgery/Chemotherapy/Radiotherapy 3
Vaccine 1
Total 54
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